Chemotherapy of first line "reinforced" for cancers of the colonist and the rectum with hepatic and/or pulmonary metastases potentially resecables: Strong association FOLFIRI and ERBITUX.

Trial Profile

Chemotherapy of first line "reinforced" for cancers of the colonist and the rectum with hepatic and/or pulmonary metastases potentially resecables: Strong association FOLFIRI and ERBITUX.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2013

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Cancer metastases; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ERBIFORT
  • Most Recent Events

    • 06 Nov 2012 Planned End Date (8 Jul 2012) added as reported by European Clinical Trials Database record.
    • 07 Aug 2012 Additional lead trial centre added as reported by European Clinical Trials Database record.
    • 04 Jul 2012 Merck KGaA and Pfizer added as associations as reported in the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top